公开(公告)号：US10155770B2

公开(公告)日：2018-12-18

申请号：US15793711

申请日：2017-10-25

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Ramin Faghih ,  Achim Moeller ,  Michael Ochse ,  Frauke Pohlki ,  Martin Schmidt ,  Kevin Sippy ,  Sean Turner ,  Elizabeth Louise Van Der Kam

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20180024144A1

公开(公告)日：2018-01-25

申请号：US15454313

申请日：2017-03-09

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-hung Lee ,  Tao Li ,  Gregory Gfesser ,  Kathleen Mortell ,  Ramin Faghih ,  Diana L. Schmidt ,  Kevin Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: G01N33/68 ,  G01N33/50 ,  C07D471/18 ,  C07D487/10

CPC classification number: G01N33/6896 ,  C07D471/18 ,  C07D487/10 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US09983218B2

公开(公告)日：2018-05-29

申请号：US15454313

申请日：2017-03-09

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-hung Lee ,  Tao Li ,  Gregory Gfesser ,  Kathleen Mortell ,  Ramin Faghih ,  Diana L. Schmidt ,  Kevin Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18 ,  G01N33/68 ,  C07D487/10 ,  G01N33/50

CPC classification number: G01N33/6896 ,  C07D471/18 ,  C07D487/10 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US20180243298A1

公开(公告)日：2018-08-30

申请号：US15563888

申请日：2016-03-30

Applicant: AbbVie Inc.

Inventor： Lawrence Black ,  Brian S. Brown ,  Bruce Clapham ,  Marlon D. Cowart ,  Michael J. Dart ,  Ramin Faghih ,  Jennifer Frost ,  Arthur R. Gomtsyan ,  Philip R. Kym ,  Huaqing Liu ,  Robert G. Schmidt ,  Lei Shi ,  Anurupa Shrestha ,  Kevin Sippy

IPC: A61K31/506 ,  A61P17/06 ,  A61P17/04

CPC classification number: A61K31/506 ,  A61P17/04 ,  A61P17/06 ,  C07D417/12 ,  C07D417/14 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

公开(公告)号：US09828381B2

公开(公告)日：2017-11-28

申请号：US15133851

申请日：2016-04-20

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Ramin Faghih ,  Achim Moeller ,  Michael Ochse ,  Frauke Pohlki ,  Martin Schmidt ,  Kevin Sippy ,  Sean Turner ,  Elizabeth Louise Van Der Kam

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D519/00

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.